Dupilumab, an antibody against IL-4 receptors, is widely used in AD therapy (Beck et al., 2014; Guttman-Yassky et al., 2019), although we speculated that its efficacy in AD treatment might involve blocking the proliferation and activation of Th2 cells and ILC2s via IL-4. This evidence concerns the gene IL4 and Alzheimer disease.